Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024
Ligand Pharmaceuticals (Nasdaq: LGND) has announced it will release its third quarter 2024 financial results before U.S. markets open on Thursday, November 7, 2024. The company will host a conference call at 8:30 a.m. ET (5:30 a.m. PT) the same day to discuss results and provide a business update. The call will be accessible via phone and webcast, with both live and replay options available.
Ligand Pharmaceuticals (Nasdaq: LGND) ha annunciato che pubblicherà i suoi risultati finanziari del terzo trimestre 2024 prima dell'apertura dei mercati statunitensi giovedì 7 novembre 2024. L'azienda terrà una conferenza telefonica alle 8:30 ET (5:30 PT) lo stesso giorno per discutere i risultati e fornire aggiornamenti sull'attività. La chiamata sarà accessibile tramite telefono e webcast, con opzioni sia per la diretta che per la registrazione.
Ligand Pharmaceuticals (Nasdaq: LGND) ha anunciado que publicará sus resultados financieros del tercer trimestre de 2024 antes de la apertura de los mercados en Estados Unidos el jueves 7 de noviembre de 2024. La compañía llevará a cabo una conferencia telefónica a las 8:30 a.m. ET (5:30 a.m. PT) el mismo día para discutir los resultados y proporcionar una actualización del negocio. La llamada será accesible por teléfono y webcast, con opciones tanto en vivo como de repetición disponibles.
리간드 제약(나스닥: LGND)이 2024년 11월 7일 목요일 미국 시장 개장 전에 2024년 3분기 재무 결과를 발표할 것이라고 발표했습니다. 회사는 같은 날 오전 8시 30분 ET(오전 5시 30분 PT)에 결과를 논의하고 비즈니스 업데이트를 제공하기 위해 전화 회의를 개최할 예정입니다. 이 통화는 전화와 웹캐스트를 통해 접근할 수 있으며, 생방송과 재생 옵션이 모두 제공됩니다.
Ligand Pharmaceuticals (Nasdaq: LGND) a annoncé qu'il publiera ses résultats financiers du troisième trimestre 2024 avant l'ouverture des marchés américains le jeudi 7 novembre 2024. La société tiendra une conférence téléphonique à 8h30 ET (5h30 PT) ce jour-là pour discuter des résultats et fournir une mise à jour sur l'entreprise. L'appel sera accessible par téléphone et par webinaire, avec des options en direct et en replay disponibles.
Ligand Pharmaceuticals (Nasdaq: LGND) hat angekündigt, dass die Finanzergebnisse für das dritte Quartal 2024 vor der Eröffnung der US-Märkte am Donnerstag, den 7. November 2024, veröffentlicht werden. Das Unternehmen wird am selben Tag um 8:30 Uhr ET (5:30 Uhr PT) eine Telefonkonferenz abhalten, um die Ergebnisse zu erörtern und ein Update zum Geschäft zu geben. Die Konferenz wird sowohl telefonisch als auch über Webcast verfügbar sein, mit Optionen für Live-Übertragungen sowie Wiederholungen.
- None.
- None.
Conference Call and Webcast Information
Date: |
Thursday, November 7, 2024 |
||
|
|
||
Time: |
8:30 a.m. ET (5:30 a.m. PT) |
||
|
|
||
Conference Call: |
(888) 596-4144 ( |
||
|
(646) 968-2525 (International) |
||
|
Conference ID is 8755336 |
||
|
|
||
Webcast: |
Live and replay webcasts of the call are available here. |
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Its business model seeks to generate value for stockholders by creating a diversified portfolio of biopharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Ligand’s goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Its business model focuses on funding programs in mid- to late-stage drug development in return for economic rights, purchasing royalty rights in development stage or commercial biopharmaceutical products and licensing its technology to help partners discover and develop medicines. Ligand partners with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate its revenue. Ligand’s Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand has established multiple alliances, licenses and other business relationships with the world’s leading biopharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. For more information, please visit www.ligand.com. Follow Ligand on X @Ligand_LGND.
We use our investor relations website and X as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our website and our X account, in addition to following our press releases, SEC filings, public conference calls and webcasts.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241023964788/en/
Investors:
Melanie Herman
investors@ligand.com
(858) 550-7761
LifeSci Advisors
Bob Yedid
bob@lifesciadvisors.com
(516) 428-8577
Media:
Kellie Walsh
media@ligand.com
(914) 315-6072
Source: Ligand Pharmaceuticals Incorporated
FAQ
When will Ligand (LGND) report Q3 2024 earnings?
What time is Ligand's (LGND) Q3 2024 earnings call?
How can I access Ligand's (LGND) Q3 2024 earnings call?
